Device Trial Radar · NCT03291743
The Biologic Onset of Crohn's Disease: A Screening Study in First Degree Relatives
Last checked: Nov 19, 2026Latest source record: Dec 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
38
Actual
Start
Feb 10, 2017
Primary completion
Sep 30, 2022
Study completion Sep 30, 2022
Sponsor
- Lead sponsor
- Carilion ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 25, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Pursuing very early diagnosis is standard of care for several diseases including colon cancer, diabetes and liver disease where an early and aggressive diagnostic and therapeutic approach has been shown to change their natural history. Crohn's disease \[CD\] still lags since commonly at presentation CD has already run a long course, often responding poorly to therapy or requiring surgery. This innovative project proposes a minimally invasive strategy - capsule endoscopy-based screening of first degree relatives \[FDR's\] of CD patients - to develop tools to diagnose CD at or near its biologic onset.
Conditions
- Crohn Disease
- Genetic Predisposition
- IBD
Interventions
Capsule endoscopyDevice
PillCam(TM) CROHN'S CAPSULE
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prevalence of Crohn's Disease in First Degree Relatives by capsule endoscopy screeningTime frame: coincident at screening
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Carilion Clinic
Roanoke, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.